scholarly journals Acute Toxicity and Hypoglycemic Effect of a Polyherbal Formulation on Blood Glucose in Oral Glucose Tolerance Test (OGTT) and Alloxan-Induced Diabetic Rats

2021 ◽  
Vol 10 (2) ◽  
pp. 111-115
Author(s):  
Abednego Okeoghene Warri ◽  
Emuesiri Goodies Moke ◽  
Aishat Oyinkansola Balogun ◽  
Kennedy Chibogu Nzeh ◽  
Emuesiri Kohworho Umukoro ◽  
...  

Madam F. Kayes Bitters® is an herbal formulation commonly used in Nigeria and some African countries in the management of diabetes mellitus and other diseases conditions. This study evaluated the in-vivo hypoglycaemic activity, as well as acute toxicity of the polyherbal formulation to provide its efficacy and safety. Healthy albino mice (20-30 g) and Sprague Dawley female rats (90-130 g) were used for this study. Acute toxicity study (LD50) of the herbal formulation was determined by methods originally described by Miller and Tainter in 1994. Following oral dosing with glucose (2 g/kg) in normal fasted animals, herbal formulation (HF) at various doses was administered and blood glucose levels at 30 minutes, 60 minutes, 90 minutes, and 120 minutes were taken and recorded. Diabetes was induced using alloxan 150 mg/kg and diabetic rats were given the HF at doses of 50, 100, and 200 mg/kg with glibenclamide 2.5 mg/kg used as standard drug treatment. Blood glucose level was determined on 1st day, 7th day, 14th and 21st day. The LD50 was greater than 5g/kg with oral administration. The oral glucose tolerance test showed that the group that received 100 mg/kg HF showed a significant reduction (p<0.05) in glucose level after 120 minutes when compared to the basal level of glucose recorded. All treated diabetic groups showed a significant decrease in glucose level on the 21st day. The herbal formulation of Hydrastis canadesis Aloe capensis, Echinacea angustifolia and honey exhibited a significant glucose-lowering activity in alloxan-induced diabetic rats.

2020 ◽  
Vol 10 (1) ◽  
pp. 61-68 ◽  
Author(s):  
Morad Hebi ◽  
Mohamed Eddouks

Background: Corrigiola telephiifolia Pourr, is a perennial species, woody distributed throughout the north of Africa. This plant is used in traditional Mediterranean preparations and has many traditional uses especially treatment of diabetes. Aim/Methods: The current research was carried out to evaluate the antidiabetic effect of Aerial Parts of Aqueous Extract (APAE) of Corrigiola telephiifolia (C. telephiifolia) on both normal and streptozotocin (STZ)-induced diabetic rats treated at a dose of 5 mg/kg for fifteen days. Additionally, the histopathological changes in the liver, morphometric analysis, Oral Glucose Tolerance Test (OGTT) in normal rats and preliminary phytochemical screening for various components were realized. Results: Single oral administration of the APAE of C. telephiifolia (5mg/kg) showed no significant change in glycaemia of normal and STZ-induced diabetic rats. In contrast, repeated oral administration of C. telephiifolia reduced blood glucose levels from 4.11 ± 0.10 mmol/L to 3.16 ± 0.16 mmol/L (p<0.01) 15 days after administration in normal rats. Furthermore, blood glucose levels decreased from 17.84 ± 1.75mmol/L to 1.93 ± 0.33 mmol/L (p<0.0001) in STZ diabetic rats after fifteen days of treatment. According to the oral glucose tolerance test, C. telephiifolia (5 mg/kg) was shown to prevent significantly the increase in blood glucose levels in normal treated rats 30 min after glucose administration when compared to the control group. Also, the liver architecture of diabetic rats treated by C. telephiifolia was improved when compared with the liver architecture of untreated diabetic rats. Concerning the preliminary phytochemical screening of C. telephiifolia, several compounds have been found such as polyphenols, flavonoids, saponins, mucilage and terpenoids. Conclusion: The results show that the aqueous extract of C. telephiifolia possesses significant antihyperglycemic activity.


2018 ◽  
Vol 5 (7) ◽  
pp. 2440-2454
Author(s):  
D. A. Omoboyowa ◽  
F. O. Afolabi ◽  
T. C. Aribigbola

Background: The anti-hyperglycemic potential of methanol stem bark extract of Anacardium occidentale (MSBEAO) was investigated using an alloxan-induced diabetic rat model. Alloxan administration induces the generation of free radicals which can affect antioxidant status resulting in the disruption of the β-cells of the pancreas. Therefore, this study examines the antioxidant potential of the plant extract and the ameliorating effect on the pancreas of alloxan-induced diabetic rats. Methods: Diabetes was induced by intraperitoneal injection of 150 mg/kg body weight of alloxan monohydrate. MSBEAO, at a concentration of 100 or 200 mg/kg b.w. was orally administered to alloxan-induced diabetic rats and normal rats. The hypoglycemic effect, oral glucose tolerance test, and biochemical assay of alloxan-induced diabetic rats were assayed using standard procedures. Results: Preliminary phytochemical screening of the extract revealed the presence of alkaloids, tannins, saponins, terpenoids, carbohydrates, and phenols at moderate concentrations. The lethality dose (LD50) of the plant extract was found to be equal to or less than 5000 mg/kg b.w. The hypoglycemic effect of the extract on the non-diabetic rats revealed a significant (p<0.05) decrease in the blood glucose concentration of animals administered with 1 g/kg b.w. of the extract, compared to normal control rats administered with normal saline. In the oral glucose tolerance test, the methanol extract exerted the highest response, similar to glibenclamide after 15 and 30 minutes of administration, compared to the control rats. The methanol extract yielded the highest blood glucose lowering effects after 9 days of treatment (p<0.05), compared to diabetic rats administered with normal saline and 0.3 mg/kg b.w. of glibenclamide. Administration of the extract at 200 mg/kg b.w. showed improved pancreas architecture and regeneration of the β-cells, compared with the pancreas of animals in the other groups. Conclusion: The results of this study suggest that MSBEAO is a potentially effective agent for the management of diabetes which might result from the antioxidant-generating capacity of the stem bark.


2012 ◽  
Vol 19 (04) ◽  
pp. 462-468
Author(s):  
M. IKRAM ◽  
SYED HAIDER HASAN ALAM ◽  
SHAFQAT MUKHTAR ◽  
M. Saeed

Introduction: Gestational diabetes mellitus is common disorder in pregnancy. It is associated with adverse pregnancy outcome. There is no consensus regarding the optimal approach to screening of gestational diabetes mellitus. The present study has tried toobserve the value of fasting blood glucose in screening of gestational diabetes. Objective: To determine the frequency of patients in whomfasting blood glucose and 100gm glucose tolerance show agreement for screening of gestational diabetes mellitus at 24 -28 wks. Studydesign: Comparative cross sectional study. Settings: The study was conducted at Gynecology and Obstetrics department Shaikh ZayedFederal Post Graduate Institute Lahore. Duration of study with dates: 6 months from 12Nov 2010 to 11 May 2011. Material and method: Thestudy included 135 booked patients with positive family history of diabetes mellitus. All patients underwent fasting blood glucose at 24-28 weeksof gestation, regardless of results of fasting blood glucose on next visit they underwent 100g oral glucose tolerance test (OGTT). The agreementbetween fasting blood glucose and 100g oral glucose tolerance test was calculated in frequency and percentages. Results: The mean age ofwomen in studied population was 27.15±3.70.Out of 135 patients 86.7 %( 117) showed agreement between results of fasting blood glucose and100g OGTT while 13.31 %( 18) showed no agreement between both of the tests. Conclusions: Fasting blood glucose is a good screeningoption for gestational diabetes mellitus along with positive history. It provides a simple, cheap and more practical test for screening of gestationaldiabetes mellitus. However diagnostic confirmation with 100g OGTT should be done.


2015 ◽  
Vol 10 (2) ◽  
pp. 326 ◽  
Author(s):  
Emordi Jonathan Emeka ◽  
Agbaje Esther Oluwatoyin ◽  
Oreagba Ibrahim Adekunle ◽  
Iribhogbe Osede Ignis

<p>The purpose of this study is to evaluate the hypoglycaemic properties and preliminary phytochemical screening of <em>Uveria chamae</em>. The hypoglycaemic properties of <em>Uveria chamae</em> was assessed on normoglycaemic rat that received single dose of the extract at 250 and 500 mg/kg body weight and blood glucose levels estimated at 2, 4, and 6 hours (single dose study). The hypoglycaemic property of the extract was also evaluated in normoglycemic rats by oral glucose tolerance test. Phytochemical screening of the extract for the presence of secondary metabolites was performed with standard methods. The extract showed a significant (p&lt;0.05) reduction in blood glucose levels at 2h and 6h compared to control.  The oral glucose tolerance test  result also showed a significant decrease (p&lt;0.05) in blood glucose levels . The study showed that the extract, <em>Uveria chamae</em> has hypoglycaemic properties which may be accounted for by the presence of the phytochemicals.</p><p> </p>


2001 ◽  
Vol 01 (02) ◽  
pp. 193-223 ◽  
Author(s):  
SARMA S. DITTAKAVI ◽  
DHANJOO N. GHISTA

Diabetes mellitus is a heterogeneous clinical syndrome characterized by hyperglycemia and long-term specific complications: retinopathy, neuropathy, nephropathy, and cardiomyopathy. Automatic neuropathy leads to visceral denervation producing a variety of clinical abnormalities: cardiac and respiratory dysrythaemias, gastrointestinal motility disorders, urinary bladder dysfunction and impotence. Diabetes mellitus is a leading cause of blindness; renal failure and limb amputation all over the world. The need to detect diabetic risk factors and treat organ disorders and complications associated with diabetes provides the impetus for us to develop the technology for assessment of diabetes, its etiology and severity, as well as for assessing the efficacy of pharmacological therapy. This paper concerns: (i) modelling of blood-glucose regulation and tolerance-testing, (ii) demonstrating patient-simulation of the blood-glucose regulatory models, by means of which the model parameters can be evaluated and related to physiological parameters, and (iii) elucidating how the glucose-regulatory system model's pole-zero representation and the blood glucose-insulin transfer-function can explain the blood glucose response data in intravenous and oral glucose tolerance tests. An easy-to-implement simple clinical-application method is developed to simulate the response of the blood-glucose regulatory model in diabetic patients during intravenous glucose tolerance test and to estimate the model parameters, which can then enable differential diagnosis of diabetes and its severity as well as in early detection of risk-to-diabetes. In the oral glucose-tolerance test, the role of the gut is to facilitate transport of glucose across the intestinal wall. The Michaelis-Menten equation, describing this enzyme-catalyzed reaction rate, can be employed to conclude that the intestinal glucose absorption rate into the blood-compartment from the gut during the oral glucose-tolerance test is constant, almost resembling a rectangular pulse Nevertheless, we have formulated a new rate-control model to simulate the oral glucose-tolerance test data, by means of the response-function of a second-order system of a single-compartment (consisting of the gut and the blood-glucose pool), with the oral glucose-bolus as the impulse-input. We have also demonstrated application of this rate-control model to patients undergoing oral glucose-tolerance test, to evaluate the model parameters. By categorizing the ranges of these parameters for normals and diabetics (varying from mild to severe), we can reliably apply this model and procedure clinically.


2020 ◽  
Vol 2020 ◽  
pp. 1-12
Author(s):  
Eko Farida ◽  
Lilis Nuraida ◽  
Puspo E. Giriwono ◽  
Betty S. L. Jenie

Some lactic acid bacteria (LAB) are observed to be potential probiotics with functional properties such as lowering fasting blood glucose (FBG), as a promising hyperglycemia management. This study investigated the ability and mechanism of Lactobacillus rhamnosus BSL and Lactobacillus rhamnosus R23 on lowering FBG in diabetic rats induced by streptozotocin (STZ). The rats were orally administered with L. rhamnosus BSL and L. rhamnosus R23 by giving 1 mL cell suspension (109 CFU/mL) daily for 30 days. The body weight (BW) was recorded once in three days, and FBG was recorded once in six days. An oral glucose tolerance test (OGTT) was measured 1 week after injection with STZ and before sacrifice. Fecal samples were collected on days 0, 15, and 30 for LAB population and identification, performed by PCR detecting 16S rRNA. Oral administration of L. rhamnosus BSL and L. rhamnosus R23 decreased FBG and improved glucose tolerance via downregulation of glucose-6-phosphatase (G6pc) expression by 0.57- and 0.60-fold change, respectively (P<0.05). The lipid profiles, BUN, creatinine, SGOT, and SGPT were significantly (P<0.05) different between normal and diabetic rats, but they were not significantly (P>0.05) different among diabetic rats. Both strains were effective in increasing fecal LAB population. Molecular identification of the isolated LAB from fecal sample indicated that they were able to survive and pass through the digestive tract. These results suggested that both strains have the ability to manage blood glucose level and become a promising agent to manage hyperglycemia and diabetes.


Sign in / Sign up

Export Citation Format

Share Document